BusinessCempra Receives Complete Response Letter From FDA For Solithromycin NDAsBy Nasdaq OMXDec 29, 2016, 11:55 AM UTC
BusinessCempra Appoints Dr. David Zaccardelli as Acting Chief Executive Officer, Promotes Chief Commercial Officer David Moore to PresidentBy Nasdaq OMXDec 12, 2016, 2:01 PM UTC
BusinessToyama Chemical (a Subsidiary of FUJIFILM Holdings Corporation) Begins Phase 3 Studies in Japan With Cempra’s SolithromycinBy Nasdaq OMXDec 5, 2016, 1:01 PM UTC
BusinessFDA Advisory Committee Votes That Efficacy Results of Cempra’s Solithromycin Outweigh Risks for Community-Acquired Bacterial PneumoniaBy Nasdaq OMXNov 5, 2016, 2:40 AM UTC
BusinessCempra Stock Trading Halted Today; FDA Advisory Committee to Discuss SolithromycinBy Nasdaq OMXNov 4, 2016, 11:05 AM UTC
BusinessCempra Receives $10 Million Milestone Payment From Toyama Chemical (a Subsidiary of FUJIFILM Holdings Corporation) as Solithromycin Progresses to Phase 3 Studies in JapanBy Nasdaq OMXNov 1, 2016, 11:30 AM UTC
